Irras AB
STO:IRRAS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
Irras AB
STO:IRRAS
|
181.7m SEK |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
194.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.7B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
130.4B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.1B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.7B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.9B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
38.7B USD |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
Irras AB
Glance View
Irras AB engages in the development, design, and commercialization of solutions for the treatment of brain pathologies. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-11-22. The company offers devices for fluid control and management for a broad range of brain pathologies, central nervous system (CNS) therapeutic applications and procedures. The offer comprises instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications called IRRAflow. The IRRAflow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor and an Occlusion Solution Mechanism into a single, integrated device. The primary market for IRRAflow is the United States. The Company’s shareholders comprise Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ) and F.EX Endotherapy Limited, among others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Irras AB is -455.7%, which is below its 3-year median of -454.3%.
Over the last 3 years, Irras AB’s Net Margin has increased from -1 989.8% to -455.7%. During this period, it reached a low of -1 989.8% on May 30, 2020 and a high of -416.5% on Dec 31, 2022.
